TESARO, Inc.
(NASDAQ : TSRO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.35%62.981.0%$472.19m
AMGNAmgen, Inc. 0.41%241.491.3%$448.51m
BIIBBiogen, Inc. -0.22%285.501.4%$387.69m
ILMNIllumina, Inc. -0.38%324.723.5%$323.34m
VRTXVertex Pharmaceuticals, Inc. 0.14%235.831.9%$300.14m
REGNRegeneron Pharmaceuticals, Inc. 0.10%385.942.6%$230.50m
EXASEXACT Sciences Corp. -1.92%88.0624.0%$205.44m
ALXNAlexion Pharmaceuticals, Inc. 0.68%113.272.0%$195.57m
ITCIIntra-Cellular Therapies, Inc. -1.43%26.259.0%$173.00m
INCYIncyte Corp. -0.15%80.502.5%$148.96m
SRPTSarepta Therapeutics, Inc. -1.84%127.9014.6%$138.72m
ARWRArrowhead Pharmaceuticals, Inc. -1.21%56.4211.3%$132.45m
SGENSeattle Genetics, Inc. 1.25%109.006.1%$122.98m
AAgilent Technologies, Inc. 0.79%90.171.6%$113.52m
BMRNBioMarin Pharmaceutical, Inc. -0.97%88.274.3%$108.30m

Company Profile

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.